Article thumbnail

Autoprocessing of human immunodeficiency virus type 1 protease miniprecursor fusions in mammalian cells

By Liangqun Huang and Chaoping Chen
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). AH: Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism.
  2. (2005). AH: Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease.
  3. (1997). Assembly, and Processing of Viral Proteins.
  4. (2007). Chokephaibulkit K: Indinavir/ritonavir remains an important component of HAART for the treatment of HIV/ AIDS, particularly in resource-limited settings. Expert Opin Drug Metab Toxicol
  5. (2008). Clore GM: Visualizing transient events in amino-terminal autoprocessing of HIV-1 protease.
  6. (1993). Craik CS: Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions.
  7. (2010). Cysteine 95 and other residues influence the regulatory effects of Histidine 69 mutations on Human Immunodeficiency Virus Type 1 protease autoprocessing. Retrovirology
  8. (1991). Deletion of sequences upstream of the proteinase improves the proteolytic processing of human immunodeficiency virus type 1. Proc Natl Acad Sci USA
  9. (1994). DM: Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein.
  10. (1983). et al: Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science
  11. (1995). Freed EO: p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. JVirol
  12. (2000). Gronenborn AM: HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol
  13. (1991). Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity.
  14. (2008). Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation.
  15. (1996). JM: A transient precursor of the HIV-1 protease. Isolation, characterization, and kinetics of maturation.
  16. (2009). Keam SJ: Darunavir: a review of its use in the management of HIV infection in adults. Drugs
  17. (2008). Kinetochore-microtubule attachment relies on the disordered N-terminal tail domain of Hec1. Curr Biol
  18. (1998). Krausslich HG: Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity.
  19. (1998). Krausslich HG: Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites.
  20. (1990). Luftig RB: Retroviral proteinases. Curr Top Microbiol Immunol
  21. (2009). Modulation of human immunodeficiency virus type 1 protease autoprocessing by charge properties of surface residue 69. J Virol
  22. (2001). Montelaro RC: Functional roles of equine infectious anemia virus Gag p9 in viral budding and infection.
  23. (2007). Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor.
  24. (1993). Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV1 protease and inhibition of assembly and budding of virus-like particles. Virology
  25. (1993). Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.
  26. (2005). Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology
  27. (1990). S: pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res
  28. (1988). Sigal IS: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA
  29. (1987). Taylor WR: A structural model for the retroviral proteases. Nature
  30. (2009). Uncoupling human immunodeficiency virus type 1 Gag and Pol reading frames: role of the transframe protein p6* in viral replication.
  31. (1998). Wainberg MA: Characterization of human immunodeficiency virus type-1 (HIV-1) particles that express protease-reverse transcriptase fusion proteins.